Exchange: OTC·Updated 03:18 PM EST

ARTH Arch Therapeutics Inc

$0.00
$0.00
(0.00%)
Today
Mkt Cap$4.00
Vol845.00

About ARTH

Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
50

Neutral Sentiment

How do you feel about ARTH?

Advertisement|Remove ads.